Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Cyclo Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q4, Cyclo Therapeutics's (NASDAQ:CYTH) reported sales totaled $585.12 thousand. Despite a 27.66% increase in earnings, the company posted a loss of $2.79 million. In Q3, Cyclo Therapeutics brought in $403.92 thousand in sales but lost $3.86 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.